3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase NA
3
Phase 1/2
2
Phase 4
1
Phase 3
1
Status
Completed
3
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Thyroid Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
Metformin
16
Cyclophosphamide
16
Drug Therapy
14
Dexamethasone
14
Cisplatin
13
Cytarabine
11
Gemcitabine
10
Radiotherapy
9
Oxaliplatin
9
Carboplatin
9
Vincristine
8
Paclitaxel
8
Idarubicin
8
Etoposide
8
Docetaxel
8
ulipristal acetate
7
icotinib
7
Sodium Chloride
7
Methotrexate
7
Fluorouracil
7
Dexmedetomidine
7
entecavir
6
Thalidomide
6
Surgical Procedures, Operative
6
Sorafenib
6
Pemetrexed
6
Leuprolide
6
Granulocyte Colony-Stimulating Factor
6
Epirubicin
6
Doxorubicin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Unknown
×
pazopanib
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled